Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.

  2. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

    Synonyms: INSULIN-LIKE GROWTH FACTOR I (HUMAN), RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I
  3. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    [L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.

  4. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    It decreases low density lipoproteins and increases high density lipoproteins.

    Products: BEZAFIBRAT AL 200, BEZAFIBRAT AL 400 RETARD
  5. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    It was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers. … CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Clenbuterol

    go.drugbank.com/drugs/DB01407
    ApprovedInvestigationalVet approved

    A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.

  7. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

  8. Drug

    Sucrose

    go.drugbank.com/drugs/DB02772
    ApprovedInvestigational

    It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener. … A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

    Products: Na
  10. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index